Selected Reads

Smartkarma

Equity Bottom-Up

Anticipation rises with the approval of Covid19 vaccines: Kinling Lo looks at this historic achievement and the issues ahead: SCMP China desk editor Josephine Ma previews the supply chain issues for the Pfizer and Moderna vaccines, price comparison with others as well as China's vaccines on the verge of officiial approval. Earth A.I CEO John Ricketts reports on global online sentiment analysis of the extent of 'vaccine anxiety', concerns over Chinese made vaccines and the response for calls to……

Real Vision managing editor Ed Harrison joins editor Max Wiethe to discuss the potentially negative jobs data that Ed is watching out for later this week. Harrison also highlights the four fiscal cliffs between now and the inauguration that could potentially cause permanent economic damage and undermine the optimism surrounding the vaccine rotation trade. They also discuss the importance of perceived duration in how certain assets react to these surprises in real economic data. In the intro,…

Morningstar

Morningstar, Inc.

Pfizer's announced acquisition of Array adds several well-positioned drugs, but we don't expect any major changes to our fair value estimate, and we continue to view Pfizer as undervalued. Strategically, Array brings Pfizer several solid marketed and pipeline drugs with a focus in oncology and rare diseases, where pricing power is typically very strong. Overall, adding Array’s drugs to Pfizer's portfolio should reinforce its wide moat
We believe the key assets in the deal are Array's approved…

Pfizer reported first-quarter results largely in line with our expectations, and we don't expect any changes to our fair value estimate. We continue to view Pfizer as undervalued, with the investment community not likely appreciating Pfizer's strong pipeline. The well-positioned pipeline along with a solid portfolio of currently marketed drugs reinforces our wide moat rating
In the quarter, total sales increased 5% with strong growth from the majority of recently launched drugs offsetting…

United States

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals.  The Company's products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00